Otsuka Pharmaceutical Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (167)

Electronic Access - Single User License $800 Buy Now
CD-ROM Mail Delivery $1200Buy Now
Hard Copy Mail Delivery $1200 Buy Now
Electronic Access - Multi-User License $1600 Buy Now


“Otsuka Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Otsuka Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “21” cancer drugs in clinical pipeline and majority of them are in phase-II. There are 10 cancer drugs by Otsuka Pharmaceuticals which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Otsuka Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Otsuka Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Otsuka Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “21” cancer drugs in clinical pipeline and majority of them are in phase-II. There are 10 cancer drugs by Otsuka Pharmaceuticals which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Otsuka Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Otsuka Pharmaceutical

  1.1 Business Overview

  1.2 Otsuka Pharmaceutical Cancer Pipeline Overview

 

2. Otsuka Pharmaceuticals Cancer Drugs in Preclinical Phase

  2.1 Cannabidiol - GW Pharmaceuticals

  2.2 Proto Oncogene Proteins C-Akt Inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

  2.3 Fibroblast Growth Factor Receptor Antagonists - Astex Pharmaceuticals/Janssen Pharmaceutica

  2.4 Cancer Therapeutics - Astex Pharmaceuticals/Janssen Pharmaceutica

  2.5 Ras/Raf Kinase Inhibitors - Institute of Cancer Research/Royal Marsden Foundation

  2.6 Cancer Vaccines - OncoTherapy Science/Otsuka Pharmaceuticals

 

3. Otsuka Pharmaceuticals Cancer Drugs in Phase-I

  3.1 OPB 111077

  3.2 OPB 111001

  3.3 AT 13148

  3.4 NLS VPAC1

  3.5 OCV C02

 

4. Otsuka Pharmaceuticals Cancer Drugs in Phase-I/II

  4.1 ASTX 660

 

5. Otsuka Pharmaceuticals Cancer Drugs in Phase-II

  5.1 Onalespib

  5.2 AT 7519

  5.3 AZD 5363

  5.4 Erdafitinib

  5.5 Dronabinol/Cannabidiol - GW Pharmaceuticals

  5.6 OCV 501

  5.7 OCV 101

 

6. Otsuka Pharmaceuticals Cancer Drugs in Phase-III

  6.1 Guadecitabine

  6.2 Ribociclib

 

7. Marketed Cancer Drugs by Otsuka Pharmaceuticals

  7.1 Ponatinib

  7.2 Atezolizumab

  7.3 Nabiximols

  7.4 Busulfan Intravenous - Otsuka Pharmaceutical

  7.5 Decitabine

  7.6 Dasatinib

  7.7 Interferon-Gamma - Hayashibara

  7.8 Ixabepilone

  7.9 Tegafur/Uracil

  7.10 Interferon Alpha-2a - Amarillo/Hayashibara

 

8. No Development Reported in Cancer Drugs in Clinical Pipeline

  8.1 Elpamotide

  8.2 GNX 8

  8.3 BRAF Inhibitors - Astex/Wellcome Trust/ICR

  8.4 JAK2 Inhibitors - Astex Therapeutics

  8.5 CEACAM6 Monoclonal Antibody – Montigen

  8.6 Haematological Malignancies Therapeutics - Astex/Institute of Cancer  Research/Cancer Research Technology

  8.7 PKM2 Modulators - Astex Pharmaceuticals

  8.8 Cancer Therapeutics - Astex Pharmaceuticals/Cancer Research Technology/Northern Institute for Cancer Research

  8.9 Methionine Aminopeptidase-2 Inhibitors - Astex Therapeutics

 

9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 Rebamipide

  9.2 Vesnarinone

  9.3 Mobenakin

  9.4 Emitefur

  9.5 Uracil Breath Test

  9.6 OCV C01

  9.7 Rubitecan

  9.8 AT 9283

  9.9 Amuvatinib

  9.10 Interleukin-1-Alpha – Otsuka

  9.11 OPB 31121

  9.12 OPB 51602

  9.13 OCV 105

  9.14 Paclitaxel Ceribate

  9.15 AO 90

  9.16 Pim Serine/Threonine Kinase Inhibitors - Astex Pharmaceuticals

  9.17 Small Molecule Drugs - Astex/Bayer HealthCare Pharmaceuticals

  9.18 Cyclin-Dependent Kinase Inhibitors - Astex Therapeutics

  9.19 OPB 3206

  9.20 Axl Receptor Tyrosine Kinase Inhibitors - Astex Pharmaceuticals

  9.21 Tumour Cell Metabolism-Based Therapeutics - Astex Pharmaceuticals

  9.22 Anti-c-erbB2-anti-CD3 Bifunctional Monoclonal Antibodies 


Figure 1-1: Otsuka Pharmaceuticals Cancer Pipeline by Phase (%)

Figure 1-2: Otsuka Pharmaceuticals Cancer Pipeline by Phase (Number)

Figure 1-3: Otsuka Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Otsuka Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)